Compare GMTL & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMTL | IPSC |
|---|---|---|
| Founded | 2021 | 2019 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 369.4M | 362.5M |
| IPO Year | 2024 | 2021 |
| Metric | GMTL | IPSC |
|---|---|---|
| Price | $13.54 | $2.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $30.00 | $4.25 |
| AVG Volume (30 Days) | 187.6K | ★ 506.9K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $8.60 | $0.44 |
| 52 Week High | $22.21 | $2.97 |
| Indicator | GMTL | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 59.18 | 59.12 |
| Support Level | $12.35 | $2.13 |
| Resistance Level | $13.82 | $2.39 |
| Average True Range (ATR) | 0.94 | 0.09 |
| MACD | 0.15 | 0.04 |
| Stochastic Oscillator | 82.28 | 95.83 |
Guardian Metal Resources PLC focuses on metals exploration and development, with a focus on precious metals exploration in North America. The Company has one business segment, which is the exploration and evaluation of mineral resources in Nevada, USA. Its exploration projects comprise the Pilot Mountain Project, Tempiute Project, Golconda Summit Project, Stonewall Project, and Garfield Project, and the Group is the operator of the Golconda Summit Project.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.